New targets for the treatment of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
10.3969/j.issn.1006-5725.2025.05.003
- VernacularTitle:异基因造血干细胞移植后急性移植物抗宿主病的治疗新靶点
- Author:
Haoliang DUAN
1
;
Yuhua RU
1
;
Jia CHEN
1
Author Information
1. 国家血液系统疾病临床医学研究中心、江苏省血液研究所、苏州大学附属第一医院血液科(江苏 苏州 215006)
- Publication Type:Journal Article
- Keywords:
haematopoietic stem cell transplantation;
acute graft-versus-host disease;
graft-versus-leukemia effect;
T cells;
antigen-presenting cells;
myeloid-derived suppressor cells;
mesenchymal stem cells;
signaling pathways
- From:
The Journal of Practical Medicine
2025;41(5):634-640
- CountryChina
- Language:Chinese
-
Abstract:
Allogeneic haematopoietic stem cell transplantation(allo-HSCT)is the most effective curative treatment for hematologic malignancies.Its efficacy hinges on eliminating primary hematological disorders and restoring bone marrow hematopoiesis during conditioning,as well as leveraging the graft-versus-leukemia(GVL)effect.However,acute graft-versus-host disease(aGVHD)remains a significant complication following allo-HSCT,substantially affecting patient survival and quality of life.Current preclinical studies focus on strategies to mitigate aGVHD while preserving adequate GVL effects to improve transplant outcomes.This review summarizes recent preclinical research findings in this field,emphasizing the regulatory roles and specific molecular mechanisms of T cells,antigen-presenting cells,myeloid-derived suppressor cells,and mesenchymal stem cells in aGVHD.It further highlights the latest therapeutic strategies for aGVHD from preclinical studies,aiming to provide valuable insights for researchers and clinicians to develop more effective therapeutic targets and strategies.
